Original Article
Analysis on the vaccination coverage of 13-valent pneumococcal conjugate vaccine in China from 2017 to 2021
Chen Yani, Hu Yingxue, Cao Lei, Zheng Hui, An Zhijie
Published 2023-10-06
Cite as Chin J Prev Med, 2023, 57(10): 1536-1541. DOI: 10.3760/cma.j.cn112150-20221222-01221
Abstract
ObjectiveTo explore the vaccination coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China from 2017 to 2021.
MethodsUsing the reported number of PCV13 administrated doses from 2017 to 2021 and the population data from 31 provinces in China, which were collected by the Immunization Program Information System and summarized data at different levels (prefecture, provincial, and national). Collecting batch release data of PCV13 during the same period through the official website of the National Institutes for Food and Drug Control. The average coverage level of PCV13 was calculated by comparing the number of PCV13 vaccinations reported annually to the number of births in that year, and the spatial auto-correlation analysis was conducted in 2021 at the prefecture level. The coverage of PCV13 vaccination was estimated by the total vaccine doses administered each year divided by the number of newborn in the year, as of the administrated dose number per 100 people.
ResultsFrom March 2017 to December 2020, the total batch release of PCV13 was 20.06 million, with a total of 71.54, 384.75, 475.45, and 10.8886 million doses each year. During the same period, PCV13 reported doses were 20.2369 million and the vaccination doses from 2017 to 2021 were 4.08, 170.46, 407.52, 599.77, and 8.4185 million doses, respectively. From 2017 to 2021, the ratio of PCV13 doses administrated per 100 infants in each year was 0.25, 10.26, 23.81, 38.16, and 69.90 doses per 100 people, respectively. The range of the ratio in each province increased from 3.85 doses in 2017 to 264.41 doses per 100 people in 2021. The spatial auto-correlation analysis results showed that based on prefecture-level cities, there was spatial clustering in a certain area of PCV13 coverage from 2017 to 2021, and the spatial correlation in 2021 was the highest. The hotspot analysis showed that the hotspot areas with high coverage levels of PCV13 were concentrated in Jiangsu, Zhejiang, Shanghai, Fujian and their surrounding areas. The cold spots with low vaccine coverage were concentrated in Yunnan, Qinghai, Tibet, and their surrounding areas.
ConclusionThe average coverage level of PCV13 is low in China with significant regional differences.
Key words:
Pneumococcal infections; Pneumococcal vaccines; Coverage; Surveillance
Contributor Information
Chen Yani
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
Hu Yingxue
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
Cao Lei
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
Zheng Hui
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
An Zhijie
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
